Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A phase I-II study of cyclocytidine was conducted in 102 patients, 96 of whom had metastatic solid tumors and six of whom had acute leukemia. The drug was administered in 5- or 10-day courses of single daily iv or sc injections of 100-675 mg/m2 day. Two complete and six partial responses were observed in 64 solid tumor patients evaluable for response, 52 of whom had malignant melanoma or adenocarcinoma of gastrointestinal origin. The median duration of the responses was 6 months. An additional seven patients achieved stabilization of their disease for greater than or equal to 2 months. No responses occurred in six patients with acute leukemia. Side effects included nausea and vomiting, postural hypotension, and parotid pain, occurring in approximatley one third of patients receiving greater than 200 mg/m2/day. No myelosuppression was observed in six patients receiving 5-day courses of 100-200 mg/m2/day. Myelosuppressive toxicity became increasingly severe with doses greater than 200 mg/m2/day x 10, related at least in part to prior chemotherapy exposure including the nitrosoureas.
 ...
PMID:Phase I-II evaluation of cyclocytidine. 6 28

The expression of HLA antigens and beta2-microglobulin (beta2-mu) on cultured melanoma cells originated from 11 patients has been quantitated and compared with that on fibroblasts and cultured human lymphoid cells originated from the same patients. No qualitative or quantitative difference was detected with the exception of one melanoma line. HLA antigens were also quantitated in sera from melanoma patients: two sera reacted with anti-HLA-B7 antibodies although this specificity was not expressed on lymphocytes from whom the sera were obtained. A technique to quantitate HLA antigens on cells developed in the course of this study is described.
 ...
PMID:Expression of histocompatibility (HLA) antigens on tumor cells and normal cells from patients with melanoma. 6 83

To identify soluble cell surface melanoma-associated antigens (MAA), human melanoma cells in culture were radioiodinated by the lactoperoxidase technique and solubilized in non-ionic detergent (NP-40). Labelled MAA were identified by a quantitative double-antibody antigen binding assay and unrelated labelled macromolecules by trichloroacetic acid precipitation. Detergent solubilized 95% of the macromolecule-associated radioactivity. Approximately 8%, presumably MAA, was bound specifically by anti-melanoma serum. In contrast, anti-melanoma serum bound specifically only 0.5 to 1.5% of the acid precipitable radioactivity in control cells iodinated in a similar manner. Specificity was further studied by quantitative serum absorption. Two different melanoma lines were equally effective in inhibiting specific binding of iodinated melanoma lysate, whereas 50-100 times more normal fresh lymphocytes, liver and spleen cells, cultured HeLa or colon adenocarcinoma cells, and 8 times more cultured fetal cells were required to produce similar reductions in specific binding. These studies demonstrate that cell surface human melanoma antigens that differ qualitatively and/or quantitatively from those on normal or malignant allogeneic tissues can be solubilized and identified. These antigens are shared with other melanomas, and some are also present on fetal cells.
 ...
PMID:Identification and solubilization of iodinated cell surface human melanoma associated antigens. 7 Apr 12

5-S-cysteinyldopa is metabolized by O-methylation on incubation with a liver extract and S-adenosyl methionine. O-methylated 5-S-cysteinyldopa isolated from melanoma urines by ion exchange and paper chromatography was identified by gas chromatography-mass spectrometry and NMR.
 ...
PMID:Metabolism of 5-S-cyteinyldopa by O-methylation. 7 Sep 21

This communication describes an automated micro-adherence inhibition assay. Tumor-specific immunity was demonstrated with B16 melanoma and MCA-38 colon adenocarcinoma, both of which are syngeneic to the same strain of mouse (C57B16/J). Abrogation of the leukocyte adherence inhibition (LAI) response of sensitized leukocytes has been demonstrated in the MCA-38 tumor system by the addition of serum from mice bearing MCA-38 progressively growing tumors, a property not present in normal serum. The sensitivity of the system has also been demonstrated by showing that LAI will change prior to a tumor becoming palpable. This microassay has the advantage of being simple, rapid and reproducible, and involves the use of minimal quantities of antigenic preparations and leukocytes, and in addition is amenable to rigorous statistical analysis.
 ...
PMID:Leukocyte adherence inhibition: an automated microassay demonstrating specific antigen recognition and blocking activity in two murine tumor systems. 7 30

A newly discovered amino acid, 5-S-cysteinyldopa, present in the urine of healthy subjects is excreted in pathological amounts in many patients suffering from melanoma metastases. Increased excretion of 5-S-cysteinyldopa may be observed before metastases become clinically evident. Determination of 5-S-cysteinyldopa is superior to determination of dopa+dopamine in the diagnosis of melanoma metastases.
 ...
PMID:5-S-cysteinyldopa in the urine of melanoma patients. 7 2

A human melanoma metastasis was found to contain a substance identical with synthetic glutathionedopa when examined by means of an automatic amino acid analyser, chromatography on a Dowex-50 column, thin-layer electrophoresis, and by fluorimetry. The presence of glutathionedopa in melanoma tissue and of enzymes capable of hydrolysing the glutathione moiety of the molecule, together with the absence of glutathionedopa in the urine, suggest that glutathionedopa is an intermediate substance in the formation of 5-S-cysteinyldopa.
 ...
PMID:Glutathionedopa in malignant melanoma. 7 25

Tumor cell fractions isolated from tumor lines SH-3 (breast carcinoma) and RPMI-7932 (malignant melanoma) by differential centrifugations were capable of transforming lymphocytes into cytotoxic effector cells. Lymphocytes cultured alone in human AB plasma did not become cytotoxic to tumor cells. However, when cultured with tumor cell fractions sedimented at 1000 X g(R1), 20,000 X g(R2), and 100,000 X g(R3), these lymphocytes became markedly cytotoxic to specific tumor targets in a 3.5-hr (51)Cr release assay. R2 fractions were significantly more immunogenic than were R3 fractions (p less than 0.05). Although lymphocytes sensitized with SH-3 tumor cell fractions were cytotoxic to SH-3 tumor cells, they were also cytotoxic to cells from RPMI-7932 and RPMI-8322 (malignant melanoma) tumor lines and vice versa. Cells from tumor lines HT-29 (colon carcinoma) and COLO 110 (ovary carcinoma) were significantly less susceptible to lysis by effector cells generated against SH-3. These immune cells, although capable of killing cells from tumor lines, were not able to lyse cells from autochthonous normal lymphoid lines or normal lymphocytes that have been transformed by phytohemagglutinin. Tumor cell fractions were not immunogenic at low (5- to 20-mul/0.75 ml) concentrations; an increase of 4- to 10- fold in their concentrations was usually followed by a decrease in immunization.
 ...
PMID:In vitro immunization against human tumor cells with tumor cell fractions. 7

CEA-like antigen has been detected on the surface of some melanoma cells using a rabbit antiserum raised against CEA antigen in 51Cr-release leucocyte-dependent cytotoxic-antibody (LDA) assays. The CEA antigen used for production of the antiserum was shown to be immunologically pure by immunoelectrophoresis procedures and reacted with a reference serum to CEA. The specificity of the CEA antiserum for CEA on the melanoma cells was further shown by removal of reactivity to melanoma cells after absorption on CEA affinity columns. LDA activity to CEA was also shown in a serum taken during pregnancy. No CEA LDA activity was found in several melanoma sera. These findings suggest that CEA may have biological significance in tumour rejection, and that CEA assays may be of value in monitoring disease activity in melanoma patients.
 ...
PMID:Detection of carcinoembryonic-like antigen on melanoma cells by leucocyte-dependent-antibody assays. 7 78

Five of 8 cell lines from human melanomas originally established elsewhere were found to consist exclusively of mouse cells when examined in our laboratory some months after their receipt. Cytogenetic studies, including G- and C-banding, showed that the mouse cells in all cultures had originated from a single cell line, identified as the L-line. Contamination probably occurred, one year before its discovery, in a laboratory where L cells and human melanoma cells were briefly kept in the same incubator.
 ...
PMID:Contamination of human melanoma cell lines by mouse L cells. 7 63


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>